2:I[6146,[],""]
3:I[4411,[],""]
4:"$Sreact.suspense"
5:I[7256,["863","static/chunks/863-822c2cde35e02348.js","185","static/chunks/app/layout-fb78cfc571d4c3d6.js"],"KeyboardNavigation"]
6:I[5407,["863","static/chunks/863-822c2cde35e02348.js","185","static/chunks/app/layout-fb78cfc571d4c3d6.js"],"SlideNavigation"]
0:["DkpgZd6XOJjDaY981EGFp",[[["",{"children":["pages",{"children":["7",{"children":["__PAGE__",{}]}]}]},"$undefined","$undefined",true],["",{"children":["pages",{"children":["7",{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white","children":["$","div",null,{"className":"flex flex-col w-full h-full","children":[["$","div",null,{"className":"flex-none bg-slate-800/90 p-6 flex items-center gap-4","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":48,"height":48,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-target text-purple-400","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","circle","1vlfrh",{"cx":"12","cy":"12","r":"6"}],["$","circle","1c9p78",{"cx":"12","cy":"12","r":"2"}],"$undefined"]}],["$","h1",null,{"className":"text-6xl font-bold text-white","children":"SWOT Analysis"}]]}],["$","div",null,{"className":"flex-1 min-h-0 grid grid-cols-2 grid-rows-2 gap-6 p-8","children":[["$","div",null,{"className":"bg-slate-800/90 border-t-4 border-green-400 rounded-lg p-6","children":[["$","div",null,{"className":"flex items-center gap-4 mb-6","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":36,"height":36,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","h3",null,{"className":"text-4xl font-bold text-green-400","children":"Strengths"}]]}],["$","div",null,{"className":"space-y-3","children":[["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"First and only FDA-approved PD-L1 inhibitor for advanced cSCC"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Differentiated ADCC mechanism beyond checkpoint blockade"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Strong clinical data: 47-48% ORR with durable responses"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Sun Pharma's global commercialization infrastructure"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Favorable safety profile for immunocompromised patients"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-green-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"$$1B+ addressable U.S. market opportunity"}]]}]]}]]}],["$","div",null,{"className":"bg-slate-800/90 border-t-4 border-orange-400 rounded-lg p-6","children":[["$","div",null,{"className":"flex items-center gap-4 mb-6","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":36,"height":36,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","h3",null,{"className":"text-4xl font-bold text-orange-400","children":"Weaknesses"}]]}],["$","div",null,{"className":"space-y-3","children":[["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400 mt-1","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Late market entry vs. established PD-1 competitors (Keytruda, Libtayo)"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400 mt-1","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Limited head-to-head clinical trial data"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400 mt-1","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Historical manufacturing delays (complete response letter)"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400 mt-1","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Pricing parity strategy limits premium positioning"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-alert text-orange-400 mt-1","children":[["$","circle","1mglay",{"cx":"12","cy":"12","r":"10"}],["$","line","1pkeuh",{"x1":"12","x2":"12","y1":"8","y2":"12"}],["$","line","4dfq90",{"x1":"12","x2":"12.01","y1":"16","y2":"16"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Pre-acquisition company had minimal revenue history"}]]}]]}]]}],["$","div",null,{"className":"bg-slate-800/90 border-t-4 border-blue-400 rounded-lg p-6","children":[["$","div",null,{"className":"flex items-center gap-4 mb-6","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":36,"height":36,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","h3",null,{"className":"text-4xl font-bold text-blue-400","children":"Opportunities"}]]}],["$","div",null,{"className":"space-y-3","children":[["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Indication expansion: Earlier-stage cSCC, other skin cancers (3-5x population)"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"European market entry: EMA/UK approvals ($250-400M potential)"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Asia-Pacific expansion via Sun Pharma network"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Combination therapy protocols with radiation/other agents"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Biomarker-driven patient selection improving outcomes"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-trending-up text-blue-400 mt-1","children":[["$","polyline","126l90",{"points":"22 7 13.5 15.5 8.5 10.5 2 17"}],["$","polyline","kwv8wd",{"points":"16 7 22 7 22 13"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Real-world evidence generation for competitive advantage"}]]}]]}]]}],["$","div",null,{"className":"bg-slate-800/90 border-t-4 border-red-400 rounded-lg p-6","children":[["$","div",null,{"className":"flex items-center gap-4 mb-6","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":36,"height":36,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","h3",null,{"className":"text-4xl font-bold text-red-400","children":"Threats"}]]}],["$","div",null,{"className":"space-y-3","children":[["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Intense competition from Keytruda/Libtayo with established market share"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Potential biosimilar competition post-patent expiration (2036+)"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Reimbursement challenges and payer utilization management"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Emerging next-generation checkpoint inhibitors"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Healthcare reform and drug pricing legislation risks"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":16,"height":16,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-triangle-alert text-red-400 mt-1","children":[["$","path","wmoenq",{"d":"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"}],["$","path","juzpu7",{"d":"M12 9v4"}],["$","path","p32p05",{"d":"M12 17h.01"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Manufacturing and supply chain vulnerabilities"}]]}]]}]]}]]}],["$","div",null,{"className":"flex-none p-4 text-right","children":["$","p",null,{"className":"text-xl text-gray-400","children":"7"}]}]]}]}],null],null],null]},[null,["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children","pages","children","7","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined"}]],null]},[null,["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children","pages","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined"}]],null]},[[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/8d323862949ffad9.css","precedence":"next","crossOrigin":"$undefined"}]],["$","html",null,{"lang":"en","className":"dark","children":["$","body",null,{"className":"__className_f367f3 h-1080px w-1920px","children":[["$","$4",null,{"fallback":null,"children":[["$","$L5",null,{}],["$","$L6",null,{}]]}],["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":[["$","title",null,{"children":"404: This page could not be found."}],["$","div",null,{"style":{"fontFamily":"system-ui,\"Segoe UI\",Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["$","div",null,{"children":[["$","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}}],["$","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":"404"}],["$","div",null,{"style":{"display":"inline-block"},"children":["$","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."}]}]]}]}]],"notFoundStyles":[]}]]}]}]],null],null],["$L7",null]]]]
7:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"Unloxcyt Market Survey - Interactive Presentation"}],["$","meta","3",{"name":"description","content":"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"}],["$","meta","4",{"name":"next-size-adjust"}]]
1:null
